Nara Organics recalls infant formula after multistate botulism outbreak

Nara Organics has recalled its Whole Milk Organic Powdered Infant Formula nationwide after federal investigators linked the product to a multistate infant botulism outbreak involving three babies in California, Pennsylvania and Washington.

The recall affects a product sold in the United States through Target stores, online and on Nara.com. The formula is manufactured in Europe. The FDA said the product represents less than 1% of U.S. infant formula sales and is not expected to cause supply shortages.

What happened

The recall followed an investigation into three infant botulism cases. The affected infants were 2 to 5 months old and were hospitalized. According to the FDA and reporting on the recall, the babies consumed Nara Organics-brand powdered infant formula before becoming ill.

AP reported that the illness reports date back to spring 2026, with a second set of cases in May. The public recall was reported on June 14, 2026.

What families should do

The CDC advised caregivers to stop using the recalled formula immediately. It also told parents and guardians to photograph opened cans, record lot numbers and use-by dates, and keep opened cans labeled DO NOT USE for at least a month before disposal if no symptoms appear.

Caregivers are also being told to watch for symptoms of infant botulism, a rare but serious illness in babies under 1 year old.

Treatment and risk

The babies in the outbreak were treated with BabyBIG, the FDA-approved treatment for infant botulism. The recall is a precaution tied to the investigation, and officials have not said they have identified the contamination source.

Testing of leftover formula is still a key open question. Regulators have also not said whether lab work has confirmed contamination in the product itself.

What comes next

Officials are expected to continue reviewing leftover formula and lot information as part of the investigation. Nara Organics may also expand its recall notice or refund instructions if regulators identify additional affected product details.

For now, the immediate guidance is to stop using the formula and follow CDC instructions for documenting any cans already opened.